SLC5A2 and stage 5 chronic kidney disease: Recently, clinical studies have shown that SGLT2 inhibitors can remarkably prevent DKD progression and the onset of end-stage renal disease independent of lowering glucose (17, 18) and, thus, as SGLT2 inhibitors, Canagliflozin and Dapagliflozin (DAPA) have been used to delay the development of DKD (19).